Structure and function of the 5HT2A-mGlu2 heteromer in schizophrenia

$362,494R01FY2016MHNIH

Virginia Commonwealth University, Richmond VA

Investigators

Linked publications & trials

Paper 38648100 Paper 38561467 Paper 37759040 Paper 37537185 Paper 37461593 Paper 37352762 Paper 37293095 Paper 36889432 Paper 36100039 Paper 35963476 Paper 35900876 Paper 35681029 Paper 35183539 Paper 34887589 Paper 34741320 Paper 34686347 Paper 34480967 Paper 34345931 Paper 33539816 Paper 33485732 Paper 33400504 Paper 33082287 Paper 32861513 Paper 32726588 Paper 32170216 Paper 31987863 Paper 31954738 Paper 31582824 Paper 31536718 Paper 31460790 Paper 31220352 Paper 30807107 Paper 30609893 Paper 30209534 Paper 30099006 Paper 30038413 Paper 30025863 Paper 29963329 Paper 28783139 Paper 28677096 Paper 28265857 Paper 28202291 Paper 28192423 Paper 28154892 Paper 28115742 Paper 27835800 Paper 27501227 Paper 27385190 Paper 26780666 Paper 26758213 Paper 26148747 Paper 26120009 Paper 25734378 Paper 25374032 Paper 25346690 Paper 23745738 Paper 23702798 Paper 23663970 Paper 23508685 Paper 23416703 Paper 23336043 Paper 23333599 Paper 23325246 Paper 23253383 Paper 23176747 Paper 23129762 Paper 22864611 Paper 22842765 Paper 22692564 Paper 22681249 Paper 22118459 Paper 21645528 Paper 21619615 Paper 21289196 Paper 21276828 Paper 20864091 Paper 20632964 Paper 20421895 Paper 19707855

Abstract

DESCRIPTION (provided by applicant): Our final goal is to mechanistically characterize the essential role of the serotonin 5-HT2A (5HT2A) receptor and the metabotropic glutamate 2 (mGlu2) receptor as a G protein-coupled receptor (GPCR) heteromeric complex in regulating receptor trafficking, signaling, and antipsychotic-like behavior. The neurotransmitters serotonin and glutamate both have been the target of considerable attention regarding psychosis and antipsychotic drug development. Family A 5HT2A and family C mGlu2 are GPCRs that have been implicated in the pathophysiology and treatment of schizophrenia and other psychotic disorders. Atypical antipsychotic drugs, such as clozapine, olanzapine and risperidone, all have in common a high affinity for the 5HT2A receptor. Recent preclinical assays in rodents suggest that drugs that activate the mGlu2 receptor represent potential new antipsychotic medications. Our previous findings demonstrate that 5HT2A and mGlu2 maintain close molecular proximity in heterologous systems and in mouse frontal cortex. Using the combination of interdisciplinary approaches in vitro, in animal models and in postmortem human brain of schizophrenic subjects, we provide evidence that the 5HT2A-mGlu2 heteromeric receptor complex is necessary for the therapeutic responses induced by atypical and glutamate antipsychotic drugs, and is potentially involved in the altered cortical processes of schizophrenia. In order to provide a better understanding of the 5HT2A-mGlu2 complex in brain function, and the foundation for the development of more effective antipsychotic drugs, we propose to characterize the basic molecular mechanisms involved in its intracellular trafficking and signaling, as well as to investigate the antipsychotic-like behavioral responses that require expression of 5HT2A and mGlu2 as a GPCR heteromer in mouse. Our results are expected to extend our understanding of the molecular basis of psychosis, and may provide a route to the identification of new and more effective drugs for the treatment of schizophrenia and other psychiatric disorders.

View original record on NIH RePORTER →